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Background: In Chile, cardiovascular disease (CVD) risk factors are controlled in as few as 30% of 
cases. Pharmacist-led medication reviews with follow up (MRF) have shown effectiveness under 
these conditions. We postulate that providing MRF in primary care in Chile could improve the 
control of CVD. 
Objectives: To evaluate the effect of MRF on CVD in primary care by assessing the clinical effect of 
MRF on older patients with CVD risk in primary care in Chile. 
Methodology: A systematic literature search was conducted to explore literature on the effect of 
MR on ambulatory CVD risk patients, including randomised and cluster randomised trials (c-RCT). 
Meta-analyses used the odds ratio (OR) for therapeutic goals and raw differences for continuous 
data, with 95% prediction intervals (PI) to account for heterogeneity. 
A c-RCT was then conducted in primary care centres in a metropolitan region of Chile. Older patients 
with moderate to high CVD risk and five or more medications were recruited from a CVD risk 
program and received either pharmacist-led MRF or usual care for a year. Generalised estimating 
equations adjusted for covariates were used for analysis during each visit. A sub-analysis of patients 
with chronic kidney disease (CKD) was conducted. 
Results: The meta-analyses included 69 studies with a total of 11 644 patients. Demographic 
characteristics were similar between studies. MRF increased the control of hypertension (OR 2.73 
[95% PI 1.05, 7.08]), type 2 diabetes mellitus (OR 3.11 [95% PI 1.17, 5.88]) and cholesterol (OR 1.91 
[95% PI 1.05, 3.46]). 
In the Polaris trial, 324 patients from 12 primary care centres (174 in the MRF group and 150 in the 
usual care group, 6 centres each) received, on average, four visits by pharmacists in one year. 




3.67 [2.13–6.33]), type 2 diabetes (6.97 [3.69–13.2]) and medication adherence (OR 6.60 [1.36–
31.9]) as well as for the number of medications (-0.86 [-1.14 to -0.58]) and CVD risk (-2.27 [-2.84 to -
1.69]). In total, 159 patients had CKD (71 in the usual care group and 88 in the MRF group). The OR 
for hypertension control was 8.41 (3.46–20.4), with reductions in systolic blood pressure (-15.3 
mmHg [-20.3 to -10.3]), serum potassium (-0.50 mEq/L [-0.65 to -0.35]), the albumin-to-creatinine 
ratio (-53.1 mg/g [-92.3 to -13.9]) and LDL cholesterol (-27.8 mg/dL [-37.6 to -17.9]). 
Conclusion: This work provides local evidence to support the implementation of MRF in primary 
care in Chile. Including pharmacists in programs for CVD could improve the quality of care for older 
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This thesis is presented in fulfilment of the doctoral degree (Doctor of Philosophy) requirements of 
the Graduate School of Health, University of Technology Sydney, Australia. 
This document was structured as a thesis by compilation. Chapter 1 presents a synopsis of the 
general approach of this thesis and research. Chapter 2 provides a background for cardiovascular 
diseases and contains the published systematic review and meta-analysis of pharmacist-led 
medication reviews and interventions, which analyse the international literature and contextualise 
the research. Chapter 3 contains information related to the burden of cardiovascular diseases in 
Chile and the role of pharmacists in the health system. Chapter 4 presents the methods and 
rationale for the Polaris trial, a cluster-randomised controlled study on medication reviews with 
follow-up in older adults with cardiovascular diseases. It was conducted in Chile as a collaborative 
effort between UTS and the Pontifical Catholic University of Chile. Chapters 5 and 6 contain papers 
on the clinical outcomes of the Polaris trial that were submitted to journals. Chapter 7 discusses the 
results and limitations. Chapter 8 presents the conclusions that arise from this research. 
Francisco Martinez Mardones is the primary author of the publications. Co-authors contributed to 
the conception or design of the work, data collection, data analysis and interpretation, and/or 
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ACR: albumin-to-creatinine ratio 
ADR: adverse drug reaction 
AF: atrial fibrillation 
BMI: body mass index 
BP: blood pressure 
CESFAM: family health centre (centro de salud familiar) 
CKD: chronic kidney disease 
CI: confidence interval 
c-RCT: cluster-randomised control trial 
CVD: cardiovascular disease 
DALY: disability-adjusted life year 
DBP: diastolic blood pressure 
DLP: dyslipidaemia 
DRP: drug-related problem 
eGFR: estimated glomerular filtration rate 
FG: fasting glucose 
FONASA: national health insurance (fondo nacional de salud) 
GEE: generalised estimating equation 
GFR: glomerular filtration rate 
GP: general practice 
HbA1c: glycated haemoglobin 
HDL: high-density lipoprotein cholesterol  
HF: heart failure 
HR: hazard ratio 
HT: hypertension 
ICC: intracluster correlation coefficient 
ISAPRE: social security health institution (instituciones de salud previsional) 




K: potassium serum level 
LDL: low-density lipoprotein cholesterol 
MAR: missing at random 
mEq/L: milliequivalents per litre 
mg/dL: milligrams per decilitre 
mg/g: milligrams per gram 
MHSC: Metropolitan Health Services Coordinator 
MI: myocardial infarction 
mL/min/1.73 m2: millilitres per min per 1.73 square meters 
mmHg: millimetres of mercury 
MR: medication reviews 
MRF: medication review with follow-up 
Na: sodium serum levels 
NCCP: national cardiovascular care program 
NCD: non-communicable diseases 
NHSC: National Health Services coordinator  
OR: odds ratio 
OECD: Organisation for Economic Co-operation and Development 
PCNE: Pharmaceutical Care Network Europe 
PPS: professional pharmacy service 
PI: prediction interval 
PP: per protocol 
SBP: systolic blood pressure 
T2DM: type 2 diabetes mellitus 
TC: total cholesterol 
TG: triglyceride 
TIDieR: Template for Intervention Description and Replication 
USD: United States dollars 
WHO: World Health Organization
